Medical Editor: John P. Cunha, DO, FACOEP
Erythromycin Lactobionate I.V. is an antibiotic used to treat various types of infections. Erythromycin Lactobionate I.V. is available in generic form. Common side effects of Erythromycin Lactobionate I.V. include:
- diarrhea or loose stools
- stomach pain, and
- pain or redness at the injection site
For the treatment of severe infections in adults and pediatric patients, the recommended intravenous dose of erythromycin lactobionate is 15 to 20 mg/kg/day. Higher doses, up to 4 g/day, may be given for severe infections. Erythromycin lactobionate may interact with theophylline, carbamazepine, digoxin, oral anticoagulants, antihistamines, cyclosporine, hexobarbital, phenytoin, alfentanil, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole. Tell your doctor all medications and supplements you use. During pregnancy, erythromycin lactobionate should be used only if prescribed. Erythromycin lactobionate passes into breast milk. Nursing women should exercise caution. Consult your doctor before breastfeeding.
Our Erythromycin Lactobionate I.V. Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Erythromycin has been associated with QT prolongation and ventricular arrhythmias, including ventricular tachycardia and torsades de pointes. (See WARNINGS.) Side effects following the use of intravenous erythromycin are rare. Occasional venous irritation has been encountered, but if the infusion is given slowly, in dilute solution, preferably by continuous intravenous infusion or intermittent infusion in no less than 20 to 60 minutes, pain and vessel trauma are minimized.
Allergic reactions ranging from urticaria to anaphylaxis have occurred. Skin reactions ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely. There have been isolated reports of reversible hearing loss occurring chiefly in patients with renal insufficiency and in patients receiving high doses of erythromycin.
Elderly patients, particularly those with reduced renal or hepatic function, may also be at increased risk for developing this effect when Erythrocin™ doses of 4 grams/day or higher are given. (See DOSAGE AND ADMINISTRATION.)
Read the entire FDA prescribing information for Erythrocin Lactobionate (Erythromycin Lactobionate)
© Erythrocin Lactobionate Patient Information is supplied by Cerner Multum, Inc. and Erythrocin Lactobionate Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.